Alzheimer's disease (AD), the most common form of dementia, is rapidly becoming a major global health concern among the elderly. Multiple pathogenic components and abnormalities in the behavior of various cell types within the CNS play a role in AD pathogenesis. The most well-studied form of neurodegenerative amyloidopathy is Alzheimer's disease (AD). Molecular pathology, aided by genomes and proteomics, is improving our understanding of neurodegenerative disease development, diagnosis, and treatment. The goal of molecular pathology is to uncover disease mechanisms by identifying molecular and pathway changes. The use of old and novel tools established in biochemistry, cell biology, molecular biology, proteomics, and genetics to the evaluation of pathological processes is at the heart of this still-evolving science. The value of molecular pathology as a supplement to histopathology in nonclinical drug development is well understood in the pharmaceutical industry.
Important Alert:
X
Title : Down’s syndrome (trisomy 21) and alzheimer disease: A common medical and scientific fight
London Jacqueline, Paris Diderot University, France
Title : Memory should be the primary endpoint in early AD
Matthias W Riepe, Ulm University, Germany
Title : Quality of life children with autism spectrum disorder
Zhenhuan Liu, Guangzhou University of Chinese Medicine, China
Title : Electrophysiology and alzheimer's pathology: A scoping review on eeg correlations with CSF biomarkers
Charikleia Karastamati, University of Pavia, Italy
Title : The vital role of care homes in supporting individuals with neurological conditions
Akankunda Veronicah, Golden Age Elderly Homes Kampala, Uganda
Title : Semantic-based memory-encoding strategy in enhancing cognitive function and daily task performance for older adults with mild cognitive impairment: A pilot non-randomised
Karen P Y Liu, Western Sydney University, Hong Kong